ARKAY Therapeutics

Advancing TriGlytza, a pancreatic beta-cell centric combination product for treating Type 2 diabetes and Covid

  • Stage Product In Development
  • Industry Other
  • Location East Windsor, NJ, USA
  • Currency USD
  • Founded August 2014
  • Employees 1
  • Incorporation Type LLC
  • Website arkaytherapeutics.com

Company Summary

ARKAY is currently advancing a pancreatic beta-centric product to the clinic. It fills clinically the most important gap that exists in the modalities that are used for the currently marketed drugs for Type II diabetes. It treats a sub population of patients with Osteoarthritis an high blood pressure who are under-served by the drugs that are on the market.

Team

Advisors

  • Alan Lewis, Ph.D. President and CEO, Diavacs, Former CEO, JDRF, Former President and CEO, Signal Pharmaceuticals, Former President, Celgene Signal Research, Former Head of Research at Wyeth-Ayerst Research, a successful serial entrepreneur
    Unconfirmed
    Casey Case, Ph.D. Senior Vice President, Asterias Biotherapeutics. As a member of senior management teams, Dr. Case has contributed to the success of several biopharmaceutical companies including: OSI Pharmaceuticals, Tularik, and Sangamo Bioscience
    Unconfirmed
    Nancy Motola, Ph.D. Former Senior Vice President, Regulatory and Quality, Alexion Pharmaceuticals, Founder, PharmaRegConnection. Dr. Motola has over 30 years experience in the pharmaceutical industry including New Haven Pharmaceuticals, Bayer Corporation.
    Unconfirmed
  • Stanley Schwartz, MD, FACP, FACE
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free